Literature DB >> 19908064

Immunosuppressive cytokine Interleukin-10 (IL-10) is up-regulated in high-grade CIN but not associated with high-risk human papillomavirus (HPV) at baseline, outcomes of HR-HPV infections or incident CIN in the LAMS cohort.

Stina Syrjänen1, Paulo Naud, Luis Sarian, Sophie Derchain, Cecilia Roteli-Martins, Adhemar Longatto-Filho, Silvio Tatti, Margherita Branca, Mojca Erzen, L S Hammes, S Costa, Kari Syrjänen.   

Abstract

Bypassing the local immunological defense reactions in the cervix is one of the prerequisites for human papillomaviruses (HPV) infections to progress to intraepithelial neoplasia (CIN). The role of potent immunosuppressive cytokines, e.g., interleukin-10 (IL-10), depressing these local virus-specific immunological responses is incompletely studied. To assess, whether IL-10 expression in cervical HPV lesions has any implications in the outcome of HPV infections or disease progression to CIN. Baseline cervical biopsies from 225 women of the LAMS study sub-cohort were analyzed for IL-10 expression using immunohistochemistry, to assess its associations with CIN grade, and high-risk HPV (HR-HPV) at baseline, as well as in predicting outcomes of HR-HPV infections, and development of incident CIN1+ and CIN2+ in this longitudinal setting. Expression of IL-10 in cervical lesions was up-regulated most often in high-grade CIN, and IL-10 over-expression retained its value as independent predictor of CIN2+ (odds ratio (OR) = 4.92) and CIN3+ (OR = 7.51) also in multivariate model, including HR-HPV and several known covariates of IL-10 expression. Up-regulation was not related to HR-HPV detection, and showed no relationship to HR-HPV viral loads. Using longitudinal predictive indicators (SE, SP, PPV, NPV), IL-10 expression was of no value in predicting (1) the outcomes of HR-HPV infections, or (2) the surrogate endpoints (incident CIN1+, CIN2+) of progressive disease. IL-10 over-expression (along with HR-HPV) was one of the independent covariates of CIN2/3. This immunosuppressive cytokine might play an important role in creating a microenvironment that favors progressive cervical disease and immune evasion by HR-HPV.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19908064     DOI: 10.1007/s00428-009-0850-7

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  36 in total

1.  Comparing PAP smear cytology, aided visual inspection, screening colposcopy, cervicography and HPV testing as optional screening tools in Latin America. Study design and baseline data of the LAMS study.

Authors:  K Syrjänen; P Naud; S Derchain; C Roteli-Martins; A Longatto-Filho; S Tatti; M Branca; M Erzen; L S Hammes; J Matos; R Gontijo; L Sarian; J Braganca; F C Arlindo; M Y S Maeda; A Lörincz; G B Dores; S Costa; S Syrjänen
Journal:  Anticancer Res       Date:  2005 Sep-Oct       Impact factor: 2.480

Review 2.  The history of papillomavirus research.

Authors:  Stina Syrjänen; Kari Syrjänen
Journal:  Cent Eur J Public Health       Date:  2008-04       Impact factor: 1.163

3.  Interleukin-10 increases Th1 cytokine production and cytotoxic potential in human papillomavirus-specific CD8(+) cytotoxic T lymphocytes.

Authors:  A D Santin; P L Hermonat; A Ravaggi; S Bellone; S Pecorelli; J J Roman; G P Parham; M J Cannon
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

Review 4.  Immune responses to human papillomavirus.

Authors:  Margaret Stanley
Journal:  Vaccine       Date:  2006-03-30       Impact factor: 3.641

5.  The in situ immunological reactivity and its significance in the clinical behavior of the cervical human papillomavirus lesions.

Authors:  K Syrjänen; M Väyrynen; M Hippeläinen; O Castrén; S Saarikoski; R Mäntyjärvi
Journal:  Neoplasma       Date:  1985       Impact factor: 2.575

6.  p16(INK4A) expression is related to grade of cin and high-risk human papillomavirus but does not predict virus clearance after conization or disease outcome.

Authors:  M Branca; M Ciotti; D Santini; L Di Bonito; C Giorgi; A Benedetto; P Paba; C Favalli; S Costa; A Agarossi; M Alderisio; K Syrjänen
Journal:  Int J Gynecol Pathol       Date:  2004-10       Impact factor: 2.762

7.  Persistent high-risk human papillomavirus infections and other end-point markers of progressive cervical disease among women prospectively followed up in the New Independent States of the Former Soviet Union and the Latin American Screening study cohorts.

Authors:  Kari Syrjänen; Irena Shabalova; Paulo Naud; Vladimir Kozachenko; Sophie Derchain; Sergej Zakharchenko; Cecilia Roteli-Martins; Raisa Nerovjna; Adhemar Longatto-Filho; Ludmila Kljukina; Silvio Tatti; Marina Branovskaja; Luciano Serpa Hammes; Margherita Branca; Valerija Grunjberga; Mojca Erzen; Luis Otavio Sarian; Anna Juschenko; Silvano Costa; Jurij Podistov; Stina Syrjänen
Journal:  Int J Gynecol Cancer       Date:  2009-07       Impact factor: 3.437

8.  Immunocompetent cells in uterine cervical lesions of human papillomavirus origin.

Authors:  K J Syrjänen
Journal:  Gynecol Obstet Invest       Date:  1983       Impact factor: 2.031

Review 9.  Interleukin-10: new perspectives on an old cytokine.

Authors:  David M Mosser; Xia Zhang
Journal:  Immunol Rev       Date:  2008-12       Impact factor: 12.988

10.  Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones.

Authors:  D F Fiorentino; M W Bond; T R Mosmann
Journal:  J Exp Med       Date:  1989-12-01       Impact factor: 14.307

View more
  8 in total

1.  Moving forward with human papillomavirus immunotherapies.

Authors:  Nicolas Çuburu; John T Schiller
Journal:  Hum Vaccin Immunother       Date:  2016-07-07       Impact factor: 3.452

2.  Local immunosuppression induced by high viral load of human papillomavirus: characterization of cellular phenotypes producing interleukin-10 in cervical neoplastic lesions.

Authors:  Thiago Theodoro Martins Prata; Camila Mareti Bonin; Alda Maria Teixeira Ferreira; Cacilda Tezelli Junqueira Padovani; Carlos Eurico dos Santos Fernandes; Ana Paula Machado; Inês Aparecida Tozetti
Journal:  Immunology       Date:  2015-07-01       Impact factor: 7.397

Review 3.  The paradox of IL-10-mediated modulation in cervical cancer.

Authors:  Yan Wang; Xiao-Hong Liu; Yue-Hong Li; Ou Li
Journal:  Biomed Rep       Date:  2013-02-26

Review 4.  Therapy of human papillomavirus-related disease.

Authors:  Peter L Stern; Sjoerd H van der Burg; Ian N Hampson; Thomas R Broker; Alison Fiander; Charles J Lacey; Henry C Kitchener; Mark H Einstein
Journal:  Vaccine       Date:  2012-11-20       Impact factor: 3.641

Review 5.  The Immune Microenvironment in Human Papilloma Virus-Induced Cervical Lesions-Evidence for Estrogen as an Immunomodulator.

Authors:  Jayshree R S
Journal:  Front Cell Infect Microbiol       Date:  2021-04-30       Impact factor: 5.293

6.  IL-10, IL-15, IL-17, and GMCSF levels in cervical cancer tissue of Tanzanian women infected with HPV16/18 vs. non-HPV16/18 genotypes.

Authors:  Adriana C Vidal; David Skaar; Rachel Maguire; Seyram Dodor; Laura W Musselwhite; John A Bartlett; Olola Oneko; Joseph Obure; Pendo Mlay; Susan K Murphy; Cathrine Hoyo
Journal:  Infect Agent Cancer       Date:  2015-03-20       Impact factor: 2.965

7.  Differential impact of IL-10 expression on survival and relapse between HPV16-positive and -negative oral squamous cell carcinomas.

Authors:  Chun-Yi Chuang; Wen-Wei Sung; Lee Wang; Wea-Long Lin; Kun-Tu Yeh; Mao-Chang Su; Chun-Han Hsin; Shiann-Yann Lee; Buor-Chang Wu; Ya-Wen Cheng; Huei Lee
Journal:  PLoS One       Date:  2012-10-31       Impact factor: 3.240

8.  Immunotherapy of human papilloma virus induced disease.

Authors:  Sjoerd H van der Burg
Journal:  Open Virol J       Date:  2012-12-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.